Cholesteryl ester transfer protein and its inhibition

Cellular and Molecular Life Sciences

Volumn 67, Issue 18, 2010, Pages 3139-3149

  Weber, Olaf ^a   Bischoff, Hilmar ^a   Schmeck, Carsten ^a   Böttcher, Michael Friedrich ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Cholesterol; Cholesteryl ester transfer protein; Dyslipidemia; High density lipoprotein; Inhibition

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; ANACETRAPIB; ATORVASTATIN; BAY 60 5521; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MK 0895; PLACEBO; TORCETRAPIB; UNCLASSIFIED DRUG; HYPOCHOLESTEROLEMIC AGENT;

ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; CONFORMATIONAL TRANSITION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILIAL HYPOALPHALIPOPROTEINEMIA; GENETIC VARIABILITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; MUTATIONAL ANALYSIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS INHIBITION; REVIEW; SINGLE DRUG DOSE; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; GENETICS; METABOLISM;

ANIMALIA;

ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; CHOLESTEROL ESTER TRANSFER PROTEINS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS;

EID: 77956627552     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-010-0418-3     Document Type: Review

References (124)

1. S Yusuf S Reddy S Ounpuu S Anand 2001 Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization Circulation 104 2746 2753 11723030
2. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults 1. (Adult Treatment Panel III) final report (2002) Circulation 106:3143-3421
3. SM Grundy JI Cleeman CN Merz HB Brewer Jr LT Clark DB Hunninghake RC Pasternak SC Smith Jr NJ Stone Coordinating Committee of the National Cholesterol Education Program 2004 Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 227 239 15249516 [Erratum, Circulation 2004;110:763]
4. JC LaRosa J He S Vupputuri 1999 Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials J Am Med Assoc 282 2340 2346
5. DB Zilversmit LB Hughes J Balmer 1975 Stimulation of cholesterol ester exchange by lipoprotein-free rabbit plasma Biochim Biophys Acta 409 393 398 173390
6. T Chajek CJ Fielding 1978 Isolation and characterization of a human serum cholesteryl ester transfer protein Proc Natl Acad Sci USA 75 3445 3449 210460
7. RJ Deckelbaum S Eisenberg Y Oschry E Butbul I Sharon T Olivecrona 1982 Reversible modification of human plasma low density lipoproteins toward triglyceride-rich precursors. A mechanism for losing excess cholesterol esters J Biol Chem 257 6509 6517 7076679
8. TL Swenson RW Brocia AR Tall 1988 Plasma cholesteryl ester transfer protein has binding sites for neutral lipids and phospholipids J Biol Chem 263 5150 5157 2833496
9. JA Glomset 1968 The plasma lecithins:cholesterol acyltransferase reaction J Lipid Res 9 155 167 4868699
10. NE Miller DS Thelle OH Forde OD Mjos 1977 The Tromsø heart-study. High-density lipoprotein and coronary heart disease: a prospective case-control study Lancet 1 8019 965 968 67464
11. DJ Gordon BM Rifkind 1989 High-density lipoprotein: the clinical implication of recent studies N Engl J Med 321 1311 1316 2677733
12. SE Borggreve HL Hillege BH Wolffenbuttel PE de Jong MW Zuurman G van der Steege A van Tol RP Dullaart PREVEND Study Group 2006 An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study J Clin Endocrinol Metab 91 3382 3388 16684835
13. P Linsel-Nitschke AR Tall 2005 HDL as a target in the treatment of atherosclerotic cardiovascular disease Nat Rev Drug Discov 4 193 205 15738977 (Erratum in: Nat Rev Drug Discov. 2005 Aug;4(8):648)
14. JA Sikorski 2006 Oral cholesteryl ester transfer protein (CETP) inhibitors: a potential new approach for treating coronary artery disease J Med Chem 49 1 1 22 16392785
15. P Parini LL Rudel 2003 Is there a need for cholesteryl ester transfer protein inhibition? Arterioscler Thromb Vasc Biol 23 374 375 12639826
16. GF Watts 2002 The Yin and Yang of cholesteryl ester transfer protein and atherosclerosis Clin Sci 103 595 597 12444912
17. T Joy RA Hegele 2009 The end of the road for CETP inhibitors after torcetrapib? Curr Opin Cardiol 24 364 371 19522058
18. H Neeli DJ Rader 2008 Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib? Cardiol Clin 26 4 537 546 18929230
19. AJM Rennings AFH Stalenhoef 2008 JTT-705: is there still future for a CETP inhibitor after torcetrapib? Expert Opin Investig Drugs 17 10 1589 1597 18808319
20. BG Brown XQ Zhao 2008 Nicotinic acid, alone or in combinations, for reduction of cardiovascular risk Am J Cardiol 101 58B 62B 18375243
21. JA Hunt Z Lu 2009 Cholesteryl ester transfer protein (CETP) inhibitors Curr Topics Med Chem 9 419 427
22. AR Tall L Yvan-Charvet N Wang 2007 The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol 27 257 260 17229967
23. AR Tall 2007 CETP inhibitors to increase HDL cholesterol levels N Engl J Med 356 1364 1366 17387130
24. AM Gotto 2007 Does torcetrapib reduce the progression of atherosclerotic disease? Nat Clin Pract Cardiovasc Med 4 478 479 17622223
25. PP Toth 2007 Reducing cardiovascular risk by targeting high-density lipoprotein cholesterol Curr Atheroscler Rep 9 1 81 88 17169252
26. LG Howes K Kostner 2007 The withdrawal of torcetrapib from drug development: implications for the future of drugs that alter HDL metabolism Expert Opin Investig Drugs 16 1509 1516 17922616
27. LK Potter DL Sprecher MC Walker FL Tobin 2009 Mechanism of inhibition defines CETP activity: a mathematical model for CETP in vitro J Lipid Res 50 11 2222 2234 19282272
28. PJ Barter HB Brewer Jr MJ Chapman CH Hennekens DJ Rader AR Tall 2003 Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis Arterioscler Thromb Vasc Biol 23 160 167 12588754
29. KR Marotti CK Castle TP Boyle AH Lin RW Murray GW Melchior 1993 Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein Nature 364 73 75 8316302
30. M Sugano N Makino S Sawada S Otsuka M Watanabe H Okamoto M Kamada A Mizushima 1998 Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits J Biol Chem 273 5033 5036 9478952
31. H Okamoto F Yonemori K Waktiani T Minowa K Maeda H Shinkai 2000 A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits Nature 406 203 207 10910363
32. Z Huang A Inazu A Nohara T Hagashita H Mabuchi 2002 Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia Clin Sci 103 587 594 12444911
33. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, Komajda M, Lopez-Sendon J, Mosca L, Tardif J, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B for the ILLUMINATE Investigators (2007) Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357:2109-2122
34. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM, for the ILLUSTRATE Investigators (2007) Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356:1304-1316
35. Kastelein JJP, Van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML; for the RADIANCE 1 Investigators (2007) Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 356:1620-1630
36. Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, Shear CL, Duggan WT, Vicari RM, Grobbee DE, Kastelein JJ, for the RADIANCE 2 Investigators (2007) Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 370:153-160
37. TA Rano E Sieber-McMaster PD Pelton M Yang KT Demarest GH Kuo 2009 Design and synthesis of potent inhibitors of cholesteryl ester transfer protein (CETP) exploiting a 1,2,3,4-tetrahydroquinoline platform Bioorg Med Chem Lett 19 2456 2460 19339179
38. GH Kuo T Rano P Pelton KT Demarest AC Gibbs WV Murray BP Damiano MA Connelly 2009 Design, synthesis, and biological evaluation of (2R, alphaS)-3,4-dihydro-2-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-5-[3- (trifluoromethoxy)-phenyl]-alpha-(trifluoromethyl)-1(2H)-quinolineethanol as potent and orally active cholesteryl ester transfer protein inhibitor J Med Chem 52 1768 1772 19236017
39. C Bruce LJ Beamer AR Tall 1998 The implications of the structure of the bactericidal/permeability increasing protein on the lipid-transfer function of the cholesteryl ester transfer protein Curr Opin Struct Biol 8 426 434 9729732
40. K Kawano SC Qin M Lin AR Tall XC Jiang 2000 Cholesteryl ester transfer protein and phospholipid transfer protein have nonoverlapping functions in vivo J Biol Chem 275 29477 29481 10893412
41. AR Tall 1993 Plasma cholesteryl ester transfer protein J Lipid Res 34 1255 1274 8409761
42. D Drayna AS Jarnagin J McLean W Henzel W Koehr C Fielding R Lawn 1987 Cloning and sequencing of human cholestryl ester transfer protein cDNA Nature 327 61234 632 634 3600759
43. LB Agellon EM Quinet TG Gillette DT Drayna ML Brown AR Tall 1990 Organization of the human cholesteryl ester transfer protein gene Biochemistry 29 6 1372 1376 2334701
44. RPF Dullaart WJ Sluiter 2008 Common variation in the CETP gene and the implications for cardiovascular disease and its treatment: an updated analysis Pharmacogenomics 9 6 747 763 18518852
45. X Qiu A Mistry MJ Ammirati BA Chrunyk RW Clark Y Cong JS Culp DE Danley TB Freeman KF Geoghegan MC Griffor SJ Hawrylik CM Hayward P Hensley LR Hoth GA Karam ME Lira DB Lloyd KM McGrath KJ Stutzman-Engwall AK Subashi TA Subashi JF Thompson IK Wang H Zhao AP Seddon 2007 Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules Nat Struct Mol Biol 14 106 113 17237796
46. XC Jiang C Bruce T Cocke S Wang M Boguski AR Tall 1995 Point mutagenesis of positively charged amino acids of cholesteryl ester transfer protein: conserved residues within the lipid transfer/lipopolysaccharide binding protein gene family essential for function Biochemistry 34 21 7258 7263 7766637
47. ME Pape RG Ulrich TJ Rea KR Marotti GW Melchior 1991 Evidence that the nonparenchymal cells of the liver are the principal source of cholesteryl ester transfer protein in primates J Biol Chem 266 20 12829 12831 1906459
48. LJ Martin PW Connelly D Nancoo N Wood ZJ Zhang G Maguire E Quinet AR Tall YL Marcel R McPherson 1993 Cholesteryl ester transfer protein and high density lipoprotein responses to cholesterol feeding in man: relationship to apoprotein E genotype J Lipid Res 34 437 446 8468527
49. T Radeau P Lau M Robb M McDonnell G Ailhaud R McPherson 1995 Cholesteryl ester transfer protein (CETP) mRNA abundance in human adipose tissue: relationship to cell size and membrane cholesterol content J Lipid Res 36 2552 2561 8847481
50. AR Tall 1993 Plasma cholesteryl ester transfer protein J Lipid Res 34 1255 1274 8409761
51. PJ Barter HB Brewer MJ Chapman CH Hennekens DJ Rader AR Tall 2003 Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis Arterioscler Thromb Vasc Biol 23 160 167 12588754
52. F Benoist P Lau M McDonnell H Doelle R Milne R McPherson 1997 Cholesteryl ester transfer protein mediates selective uptake of high density lipoprotein cholesteryl esters by human adipose tissue J Biol Chem 272 38 23572 23577 9295295
53. M Guérin PJ Dolphin MJ Chapman 1994 Preferential cholesteryl ester acceptors among the LDL subspecies of subjects with familial hypercholesterolemia Arterioscler Thromb 14 679 685 8172845
54. C Bruce WS Davidson P Kussie S Lund-Katz MC Phillips R Ghosh AR Tall 1995 Molecular determinants of plasma cholesteryl ester transfer protein binding to high density lipoprotein J Biol Chem 270 19 11532 11542 7744792
55. RJ Deckelbaum E Granot Y Oschry L Rose S Eisenberg 1984 Plasma triglyceride determines structure-composition in low and high density lipoproteins Arteriosclerosis 4 225 231 6712536
56. JA Hamilton RJ Deckelbaum 2007 Crystal structure of CETP: new hopes for raising HDL to decrease risk of cardiovascular disease? Nat Struct Mol Biol 14 95 97 17277799
57. A Kontush MJ Capman 2006 Functionally defective HDL: a new therapeutic target at the crossroads of dyslipidemia, inflammation and atherosclerosis Pharmacol Rev 3 342 374
58. A Kontush M Guerin MJ Chapman 2008 Spotlight on HDL-raising therapies: insights from the torcetrapib trials Nat Clin Pract Cardiovasc Med 5 6 329 336 18431367
59. JA Glomset 1968 The plasma lecithin:cholesterol acyltransferase reaction J Lipid Res 9 155 167 4868699
60. R Ross JA Glomset 1973 Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis Science 180 1332 1339 4350926
61. JJ Badimon L Badimon V Fuster 1990 Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit J Clin Invest 85 1234 1241 2318976
62. PR Moreno J Sanz V Fuster 2009 Promoting mechanisms of vascular health J Am Coll Cardiol 53 25 2315 2325 19539140
63. PG Yancey AE Bortnick G Kellner-Weibel M de-la Llera-Moya MC Phillips GH Rothblat 2003 Importance of different pathways of cellular cholesterol efflux Arterioscler Thromb Vasc Biol 23 712 719 12615688
64. Y Takahashi JD Smith 1999 Cholesterol efflux to apolipoprotein A1 involves endocytosis and re-secretion in a calcium-dependent pathway Proc Natl Acad Sci USA 96 11358 11363 10500181
65. DL Williams MA Connelly RE Temel S Swarnakar MC Phillips M de la Llera-Moya GH Rothblat 1999 Scavenger receptor BI and cholesterol trafficking Curr Opin Lipidol 10 329 339 10482136
66. HB Brewer Jr 2004 High-density lipoproteins: a new potential therapeutic target for the prevention of cardiovascular disease Arterioscler Thromb Vasc Biol 24 3 387 391 15003970
67. CC Schwartz ZR Vlahcevic M Berman JG Meadows RM Nisman L Swell 1982 Central role of high density lipoprotein in plasma free cholesterol metabolism J Clin Invest 70 1 105 116 6953075
68. CC Schwartz ZR Vlahcevic LG Halloran L Swell 1981 An in vivo evaluation in man of the transfer of esterified cholesterol between lipoproteins and into the liver and bile Biochim Biophys Acta 663 1 143 162 7011409
69. CC Schwartz M Berman ZR Vlahcevic LG Halloran DH Gregory L Swell 1978 Multicompartmental analysis of cholesterol metabolism in man. Characterization of the hepatic bile acid and biliary cholesterol precursor sites J Clin Invest 61 2 408 423 621281
70. GF Lewis DJ Rader 2005 New insights into the regulation of HDL metabolism and reverse cholesterol transport Circ Res 96 1221 1232 15976321
71. V Petoumenos G Nickenig N Werner 2008 High density lipoprotein exerts vasculoprotection via endothelial progenitor cells J Cell Mol Med 13 11 4623 4635
72. PJ Barter PW Baker KA Rye 2002 Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells Curr Opin Lipidol 13 285 288 12045398
73. A Kontush MJ Chapman 2006 Antiatherogenic small, dense HDL-guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 3 342 374
74. G Atzmon M Rincon P Rabizadeh N Barzilai 2005 Biological evidence for inheritance of exceptional longevity Mech Ageing Dev 126 341 345 15621216
75. N Barzilai G Atzmon C Schechter EJ Schaefer AL Cupples R Lipton S Cheng AR Shuldiner 2003 Unique lipoprotein phenotype and genotype associated with exceptional longevity J Am Med Assoc 290 2030 2040
76. JD Curb RD Abbott BL Rodriguez K Masaki R Chen DS Sharp AR Tall 2004 A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly J Lipid Res 45 948 953 14967821
77. G Franceschini M Sirtori G Gianfranceschi CR Sirtori 1981 Relation between the HDL apoproteins and AI isoproteins in subjects with the AIMilano abnormality Metab Clin Exp 30 5 502 509 6785551
78. G Franceschini L Calabresi 2007 Normal vascular function despite low levelsof high-density lipoprotein cholesterol in carriers of the apolipoprotein A-I-Milano mutant Circulation 116 2165 2172 17967773
79. G Franceschini L Calabresi G Chiesa C Parolini CR Sirtori M Canavesi F Bernini 1999 Increased cholesterol efflux potential of sera from apoAI Milano carriers and transgenic mice Arterioscler Thromb Vasc Biol 19 1257 1262 10323777
80. L Calabresi M Canavesi F Bernini G Franceschini 1999 Cell cholesterol efflux to reconstituted high-density lipoproteins containing the apolipoprotein A-IMilano dimer Biochemistry 38 16307 16314 10587455
81. JK Bielicki MN Oda 2002 Apolipoprotein A-IMilano and apolipoprotein A-IParis exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I Biochemistry 41 2089 2096 11827556
82. L Wang BG Sharifi T Pan L Song A Yukht PK Shah 2006 Bone marrow transplantation shows superior atheroprotective effects of gene therapy with apolipoprotein A-I Milano compared with wild-type apolipoprotein A-I in hyperlipidemic mice J Am Coll Cardiol 48 1459 1468 17010811
83. C Parolini G Chiesa E Gong S Caligari MM Cortese T Koga TM Forte EM Rubin 2005 Apolipoprotein A-I and the molecular variant apoAIMilano: evaluation of the antiatherogenic effects in knock-in mouse model Atherosclerosis 183 222 229 16285990
84. C Lebherz J Sanmiguel J Wilson D Rader 2007 Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent Cardiovasc Diabetol 6 15 17475009
85. SE Nissen T Tsunoda EM Tuzcu P Schoenhagen CJ Cooper M Yasin GM Eaton MA Lauer WS Sheldon CL Grines S Halpern T Crowe JC Blankenship R Kerensky 2003 Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial JAMA 290 2292 2300 14600188
86. SJ Nicholls EM Tuzcu T Crowe I Sipahi P Schoenhagen S Kapadia SL Hazen CC Wun M Norton F Ntanios SE Nissen 2006 Relationship between cardiovascular risk factors and atherosclerotic disease burden measured by intravascular ultrasound J Am Coll Cardiol 47 1967 1975 16697312
87. ET Alexander GL Weibel MR Joshi C Vedhachalam M de la Llera-Moya GH Rothblat MC Phillips DJ Rader 2009 Macrophage reverse cholesterol transport in mice expressing apoA-I Milano Arterioscler Thromb Vasc Biol 29 1496 1501 19661486
88. A Inazu EM Quinet S Wang ML Brown S Stevenson ML Barr P Moulin AR Tall 1992 Alternative splicing of the mRNA encoding human cholesteryl ester transfer protein Biochemistry 31 2352 2358 1540591
89. E Quinet TP Yang C Marinos A Tall 1993 Inhibition of the cellular secretion of cholesteryl ester transfer protein by a variant protein formed by alternative splicing of mRNA J Biol Chem 268 16891 16894 8349580
90. S Yamashita KI Hirano N Sakai Y Matsuzawa 2000 Molecular biology and pathophysiological aspects of plasma cholesteryl ester transfer protein Biochim Biophys Acta 1529 257 275 11111094
91. K Hirano S Yamashita N Nakajima T Arai T Maruyama Y Yoshida M Ishigami N Sakai K Kameda-Takemura Y Matsuzawa 1997 Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omaguri area of Japan Arterioscler Thromb Vasc Biol 17 1053 1059 9194754
92. M Nagano S Yamashita K Hirano M Takano T Maruyama M Ishihara Y Sagehashi T Kujiraoka K Tanaka H Hattori N Sakai N Nakajima T Egashira Y Matsuzawa 2004 Molecular mechanisms of cholesteryl ester transfer protein deficiency in Japanese J Atheroscler Thromb 11 3 110 121 15256762
93. J Rhyne MJ Ryan C White T Chimonas M Miller 2006 The two novel CETP mutations Gln87X and Gln165X in a compound heterozygous state are associated with marked hyperalphalipoproteinemia and absence of significant coronary artery disease J Mol Med 84 647 650 16855848
94. S Zhong DS Sharp JS Grove C Bruce K Yano AR Tall 1996 Increased coronary heart disease in Japanese American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels J Clin Invest 97 2917 2923 8675707
95. PS MacLean S Vadlamudi KG Mac Donald WJ Pories HA Barakat 2005 Suppression of hepatic cholesteryl ester transfer protein expression in obese humans with the development of type 2 diabetes mellitus J Clin Endocrinol Metabol 90 2250 2258
96. GK Hovingh E de Groot W van der Steeg SM Boekholdt BA Hutten JA Kuivenhoven JJ Kastelein 2005 Inherited disorders of HDL metabolism and atherosclerosis Curr Opin Lipidol 16 139 145 15767853
97. SM Boekholdt JF Thomson 2005 Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease J Lipid Res 44 1080 1093
98. A Thompson E DiAngelantonio N Sarwar S Erqou D Salcheen RPF Dillaart B Keavney Z Ye J Danesh 2008 Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk JAMA 299 23 2777 2788 18560005
99. CR Sirtori G Mombelli 2008 Viability of developing CETP inhibitors Cardiovasc Ther 26 135 146 18485135
100. LB Agellon A Walsh T Ayek P Moulin XC Jiang SA Shelanski JL Breslow AR Tall 1991 Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice J Biol Chem 266 10796 10801 2040599
101. XC Jiang L Masucci-Magoulas J Mar M Lin A Walsh JL Breslow A Tall 1993 Down-regulation of mRNA for the low density lipoprotein receptor in transgenic mice containing the gene for human cholesteryl ester transfer protein: mechanism to explain accumulation of lipoprotein B particles J Biol Chem 268 27406 27412 8262982
102. T Haraki A Inazu K Yagi K Kajinami J Koizumi H Mabuchi 1997 Clinical characteristics of double heterozygotes with familial hypercholesterolemia and cholesteryl ester transfer protein deficiency Atherosclerosis 132 229 236 9242969
103. SM Boekholdt JA Kuivenhoven NJ Wareham RJG Peters JW Jukema R Luben SA Bingham NE Day JJP Kastelein KT Khaw 2004 Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk Population Study Circulation 110 1418 1423 15337694
104. GJ De Grooth TJ Smilde S van Wissen AHEM Klerkx AH Zwinderman JC Fruchart JJP Kastelein AFH Stalenhoef JA Kuivenhoven 2004 The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia Atherosclerosis 173 261 267 15064100
105. MH Davidson K Maki D Umporowicz A Wheeler C Rittershaus U Ryan 2003 The safety and immunogenicity of a CETP vaccine in healthy adults Atherosclerosis 169 113 120 12860257
106. LJ Thomas RA Hammond EM Forsberg KM Geoghegan-Barek BH Karalius HC Marsh Jr CW Ritterhaus 2009 Co-administration of a CpG adjuvant (VaxImmune, CPG 7909) with CETP vaccines increased immunogenicity in rabbits and mice Hum Vaccin 5 2 79 84 18670196
107. RW Clark RB Ruggeri D Cunningham MJ Bamberger 2006 Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action J Lipid Res 47 537 552 16326978
108. RW Clark TA Sutfin RB Ruggeri AT Willauer ED Sugarman G Magnus-Aryitey PG Cosgrove TM Sand RT Wester JA Williams ME Perlman MJ Bamberger 2004 Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib Arterioscler Thromb Vasc Biol 24 490 497 14739125
109. MH Davidson JM McKenney CL Shear JH Revkin 2006 Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels J Am Coll Cardiol 48 1774 1781 17084249
110. JM Mc Kenney MH Davidson CL Shear JH Revkin 2006 Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin J Am Coll Cardiol 48 1782 1790
111. X Hu JD Dietz C Xia Knight DR Loging Smith AH WT H Yuan DA Perry J Keiser 2009 Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition Endocrinology 50 5 2211 2219
112. MJ Forrest D Bloomfield RJ Briscoe PN Brown AM Cumiskey J Ehrhart JC Hershey WJ Keller X Ma HE McPherson E Messina LB Peterson W Sharif-Rodriguez PK Siegl PJ Sinclair CP Sparrow AS Stevenson SY Sun C Tsai H Vargas M Walker 3rd SH West V White RF Woltmann 2008 Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone Br J Pharmacol 154 1465 1473 18536749
113. C Schmeck H Gielen-Haertwig A Vakalopoulos H Bischoff V Li G Wirtz O Weber 2010 Novel tetrahydrochinoline derived CETP inhibitors Bioorg Med Chem Lett 20 5 1740 1743 20137927 Epub 2010 Jan 21
114. Boettcher M, Heinig R, Schafer A, Wensing G (2008) Safety, tolerability, pharmacodynamics and pharmacokinetics of BAY 60-5521-a new CETP inhibitor. 0th World Conf Clin Pharmacol Ther (July 27-August 1, Quebec), 2008, Abstract T2H023
115. K Maeda H Okamoto H Shinkai 2004 S-(2-(acylamino)phenyl) 2,2-dimethylpropanethioates as CETP inhibitors Bioorg Med Chem Lett 14 10 2589 2591 15109658
116. H Shinkai K Maeda T Yamasaki H Okamoto I Uchida 2000 Bis(2-(Acylamino) phenyl) disulfides, 2-(acylamino)benzenethiols, and S-(2-(acylamino)phenyl) alkanethioates as novel inhibitors of cholesteryl ester transfer protein J Med Chem 43 19 3566 3572 11000011
117. GJ De Grooth JA Kuivenhoven AF Stalenhoef J de Graaf AH Zwinderman JL Posma A van Tol JJ Kastelein 2002 Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study Circulation 105 18 2159 2165 11994249
118. Stein EA, Stroes ESG, Steiner G, Buckley BM DPhild, Capponi AM, Burgess T, Niesor EJ, Kallend D, Kastelein JJP (2009) Safety and Tolerability of dalcetrapib. Am J Cardiol 104:82-91
119. R Krishna MS Anderson AJ Bergman B Jin M Fallon J Cote K Rosko C Chavez-Eng R Lutz DM Bloomfield M Gutierrez J Doherty F Bieberdorf J Chodakewitz KM Gottesdiener JA Wagner 2007 Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomized placebo-controlled phase I studies Lancet 370 9603 1907 1914 18068514
120. Bloomfield D, Carlson GL, Sapre A, Tribble D, McKenney JM, Littlejohn TW 3rd, Sisk CM, Mitchel Y, Pasternak RC (2009) Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J 157(2):352-360.e2. Epub 2008 Dec 20
121. D Cunningham W Lin LR Hoth DE Danley RB Ruggeri KF Geoghegan BA Chrunyk JG Boyd 2008 Biophysical and biochemical approach to locating an inhibitor binding site on cholestreyl ester transfer protein Bioconjug Chem 19 1604 1613 18646836
122. H Okamoto F Yonemori K Wakitani T Minowa K Maeda H Shinkai 2000 A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits Nature 406 203 207 10910363
123. RW Clark RB Ruggeri D Cunningham MJ Bamberger 2006 Description of the torcetrabip series of cholesteryl ester transfer protein inhibitors, including mechanism of action J Lipid Res 47 537 552 16326978
124. Cannon CP, Dansky HM, Davidson M, Gotto AM Jr., Brinton EA, Gould AL, Stepanavage M, Liu SX, Shah S, Rubino J, Gibbons P, Hermanowski-Vosatka A, Binkowitz B, Mitchel Y, Barter P, DEFINE investigators Design of the DEFINE trial (2009) Determining the efficacy and tolerability of CETP INhibition with AnacEtrapib. Am Heart J 158(4):513-519.e3